NCT01950156View on ClinicalTrials.gov

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant

Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A\*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant.

Trial Locations (1)

520-2192

Shiga University of Medical Science Hospital, Ōtsu

All Listed Sponsors
collaborator

Tokyo University

OTHER

lead

Shiga University

OTHER

NCT01950156 - Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter